source
- Allogene CEO David Chang to step down as Agios drug misses mid-stage trial resultsAllogene announced that its chief executive, co‑founder David Chang, will leave the role after an eight‑year tenure. Chang, who previously worked at Kite Pharma, will remain on the company’s board…
- Former FDA official says leadership turnover won’t derail push for faster US drug trialsThe Food and Drug Administration has faced a wave of leadership changes this year, creating uncertainty about its ability to keep drug development moving quickly. Industry leaders and regulators, h…